Logo

American Heart Association

  2
  0


Final ID: MDP753

L-2-hydroxyglutarate Attenuates the Accumulation of Long Chain Acylcarnitines in Myocardial Ischemia

Abstract Body (Do not enter title and authors here): Mammalian cells have several adaptive mechanisms to counteract the adverse effects of metabolic and redox stress induced by ischemia. Hypoxia, a hallmark of ischemia, results in the selective reduction of the tricarboxylic acid cycle metabolite, α-ketoglutarate, to the L-(S)-enantiomer of 2-hydroxyglutarate (L2HG) in several cell types. L2HG protects hypoxic cells by buffering increases in the NADH/NAD+ redox couple and inhibiting mitochondrial electron transport. In addition, the accumulation of L2HG induced by genetic knockout of L2HG dehydrogenase (L2HGDH), the only known enzyme capable of oxidizing L2HG back to α-ketoglutarate, protects mice against myocardial injury during ischemia. This protection by L2HG manifests as decreased myocardial infarct size and improved cardiac function, owing partly to a metabolic shift in carbon flux from glycolysis towards the pentose phosphate pathway. However, myocardial ischemia also leads to perturbations in fatty acid metabolism as manifest by accumulation of acylcarnitines and acyl-CoA’s. It remains unclear as to whether or not L2HG accumulation affects fatty acid metabolic homeostasis during myocardial ischemia. Here, we induced L2HG accumulation by homozygous deletion of the l2hgdh gene in male mice (l2hgdh-/-; n=12). Hearts isolated from these mice and their wild-type littermates (l2hgdh+/+; n=13) were subjected to ex vivo Langendorff perfusion at coronary perfusion pressure of 80 mmHg for 30 min with (ischemic group) or without (control group) subsequent perfusion at ~10% pressure for 90 min. Using liquid chromatography tandem mass spectrometry (LC-MS/MS)-based nontargeted lipidomics, we identified several species of long chain acylcarnitines that accumulated by ischemia in hearts obtained from L2HGDH+/+ mice [linoleoyl carnitine, palmitoyl carnitine, and hydroxy-linoleoyl carnitine increased by 13.2-fold (p=4.2 x 10-6), 10.7-fold (p=1.7 x 10-6), and 10.0-fold (p=5.8 x 10-6), respectively]. Interestingly, however, this accumulation was attenuated substantially in ischemic hearts obtained from L2HGDH-/- mice [hydroxy-linoleoyl carnitine, palmitoyl carnitine, and linoleoyl carnitine were downregulated by 62.6% (p=0.034), 54.2% (p=0.018), and 35.4% (p=0.054) in ischemic hearts from L2HGDH-/- mice when compared to L2HGD+/+ littermates]. Overall, these findings highlight a novel and potentially important role for L2HG in restoring the perturbations in fatty acid metabolism induced by myocardial ischemia.
  • Vigder, Niv  ( Brigham and Women's Hospital , Boston , Massachusetts , United States )
  • He, Huamei  ( Brigham and Women's Hospital, HMS , Boston , Massachusetts , United States )
  • Tumanov, Sergey  ( Heart Research Institute , Newtown , New South Wales , Australia )
  • Watermeyer, Georgia  ( Heart Research Institute , Newtown , New South Wales , Australia )
  • Mulhern, Ryan  ( BRIGHAM AND WOMENS , Boston , Massachusetts , United States )
  • Cordwell, Stuart  ( The University of Sydney, Australia , Sydney , New South Wales , Australia )
  • Loscalzo, Joseph  ( HARVARD MEDICAL SCHOOL , Boston , Massachusetts , United States )
  • Author Disclosures:
    Niv Vigder: DO NOT have relevant financial relationships | Huamei He: DO NOT have relevant financial relationships | Sergey Tumanov: DO NOT have relevant financial relationships | Georgia Watermeyer: DO NOT have relevant financial relationships | Ryan Mulhern: DO NOT have relevant financial relationships | Stuart Cordwell: No Answer | Joseph Loscalzo: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Myocardial Infarction: Pathophysiology Mechanisms and Therapeutics Development

Sunday, 11/17/2024 , 11:10AM - 12:35PM

Moderated Digital Poster Session

More abstracts on this topic:
ALPACAR Phase 2 Trial of Zerlasiran: Multiple doses of a Small-Interfering RNA Targeting Lipoprotein(a) with 60 weeks Folow Up.

Nissen Steven, Dorresteijn Jannick, Fok Henry, Rider David, Romano Steve, Wolski Kathy, Rambaran Curtis, Wang Qiuqing, Nicholls Stephen, Navar Ann Marie, Ray Kausik, Schwartz Gregory, Szarek Michael, Stroes Erik, Troquay Roland

Accelerometer-Measured Sedentary Behavior and Future Cardiovascular Disease

Ajufo Ezimamaka, Kany Shinwan, Ramo Joel, Churchill Timothy, Guseh James, Aragam Krishna, Ellinor Patrick, Khurshid Shaan

More abstracts from these authors:
Regulation of Vascular Smooth Muscle Cell Phenotype and Metabolic Profile by CD70

Pandey Arvind, Das Apabrita, Waldeck-weiermair Markus, Yadav Shambhu, Oldham William, Michel Thomas, Loscalzo Joseph

Deciphering the Mechanism of Action of Drug Combinations by Boolean Modeling of Transcriptomes: a Case Study of Atorvastatin/Simvastatin and Ezetimibe

Wang Ruisheng, Pedrelli Matteo, Ahmed Osman, Garagnani Paolo, Parini Paolo, Loscalzo Joseph

You have to be authorized to contact abstract author. Please, Login
Not Available